Speculative M&A Transaction Analysis, page-721

I understand the lead dose to be Bis in the all comers trial to test for changes in FTO levels before another synergetic drug is administered. I would also assume that the combined Bis/(dox?) regimes would be SOC high dosing. Doesn't Bis work best as an FTO inhibitor at low doses so how is the upcoming trial really going to highlight BiS as a FTO inhibitor? I would assume the data will be limited and once another drug other than Bis is administered how do you prove it was Bis and not the other drug. Everything all sounds rosy but Id put my neck out and say Bis would need a seperate low dose regime to prove its worth as an FTO inhibitor in the clinic. The company is pursuing the CPACs path now and from memory it needs higher dosing for it to be effective at protecting human cardiomyocytes from the toxicity of accompanying drug given in combo. If only they had more money.